These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 36583451

  • 21. Exosomes from Irradiated Nonsmall Cell Lung Cancer Cells Reduced Sensitivity of Recipient Cells to Anaplastic Lymphoma Kinase Inhibitors.
    Wu H, Zeng C, Ye Y, Liu J, Mu Z, Xie Y, Chen B, Nong Q, Wu D.
    Mol Pharm; 2018 May 07; 15(5):1892-1900. PubMed ID: 29595984
    [Abstract] [Full Text] [Related]

  • 22. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.
    Kim S, Kim TM, Kim DW, Go H, Keam B, Lee SH, Ku JL, Chung DH, Heo DS.
    J Thorac Oncol; 2013 Apr 07; 8(4):415-22. PubMed ID: 23344087
    [Abstract] [Full Text] [Related]

  • 23. Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.
    Zhang L, Jiang T, Li X, Wang Y, Zhao C, Zhao S, Xi L, Zhang S, Liu X, Jia Y, Yang H, Shi J, Su C, Ren S, Zhou C.
    Cancer; 2017 Aug 01; 123(15):2927-2935. PubMed ID: 28346673
    [Abstract] [Full Text] [Related]

  • 24. [Research Progress of Acquired Resistance Mediated by MET Amplification 
in Advanced Non-small Cell Lung Cancer].
    Pan S, Wang N, Song X.
    Zhongguo Fei Ai Za Zhi; 2022 Aug 20; 25(8):615-621. PubMed ID: 36002199
    [Abstract] [Full Text] [Related]

  • 25. Oncogene addiction and radiation oncology: effect of radiotherapy with photons and carbon ions in ALK-EML4 translocated NSCLC.
    Dai Y, Wei Q, Schwager C, Hanne J, Zhou C, Herfarth K, Rieken S, Lipson KE, Debus J, Abdollahi A.
    Radiat Oncol; 2018 Jan 05; 13(1):1. PubMed ID: 29304828
    [Abstract] [Full Text] [Related]

  • 26. Heparin-binding epidermal growth factor-like growth factor and transforming growth factor-alpha in human non-small cell lung cancers.
    Chong IW, Lin SR, Lin MS, Huang MS, Tsai MS, Hwang JJ.
    J Formos Med Assoc; 1997 Aug 05; 96(8):579-85. PubMed ID: 9290266
    [Abstract] [Full Text] [Related]

  • 27. Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.
    Isozaki H, Ichihara E, Takigawa N, Ohashi K, Ochi N, Yasugi M, Ninomiya T, Yamane H, Hotta K, Sakai K, Matsumoto K, Hosokawa S, Bessho A, Sendo T, Tanimoto M, Kiura K.
    Cancer Res; 2016 Mar 15; 76(6):1506-16. PubMed ID: 26719536
    [Abstract] [Full Text] [Related]

  • 28. Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities.
    Hung WY, Chang JH, Cheng Y, Chen CK, Chen JQ, Hua KT, Cheng CW, Hsiao M, Chung CL, Lee WJ, Chien MH.
    Cell Physiol Biochem; 2018 Mar 15; 51(1):337-355. PubMed ID: 30453282
    [Abstract] [Full Text] [Related]

  • 29. Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.
    Tartarone A, Lazzari C, Lerose R, Conteduca V, Improta G, Zupa A, Bulotta A, Aieta M, Gregorc V.
    Lung Cancer; 2013 Sep 15; 81(3):328-336. PubMed ID: 23809060
    [Abstract] [Full Text] [Related]

  • 30. EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
    Chang H, Sung JH, Moon SU, Kim HS, Kim JW, Lee JS.
    Yonsei Med J; 2017 Jan 15; 58(1):9-18. PubMed ID: 27873490
    [Abstract] [Full Text] [Related]

  • 31. EGFR is dispensable for c-Met-mediated proliferation and survival activities in mouse adult liver oval cells.
    Martínez-Palacián A, Del Castillo G, Herrera B, Fernández M, Roncero C, Fabregat I, Sánchez A.
    Cell Signal; 2012 Feb 15; 24(2):505-513. PubMed ID: 22001397
    [Abstract] [Full Text] [Related]

  • 32. Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.
    Sugano T, Seike M, Noro R, Soeno C, Chiba M, Zou F, Nakamichi S, Nishijima N, Matsumoto M, Miyanaga A, Kubota K, Gemma A.
    Mol Cancer Ther; 2015 Nov 15; 14(11):2433-40. PubMed ID: 26351321
    [Abstract] [Full Text] [Related]

  • 33. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ, Shapiro GI.
    Curr Opin Investig Drugs; 2010 Dec 15; 11(12):1477-90. PubMed ID: 21154129
    [Abstract] [Full Text] [Related]

  • 34. Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models.
    Fang DD, Tao R, Wang G, Li Y, Zhang K, Xu C, Zhai G, Wang Q, Wang J, Tang C, Min P, Xiong D, Chen J, Wang S, Yang D, Zhai Y.
    BMC Cancer; 2022 Jul 11; 22(1):752. PubMed ID: 35820889
    [Abstract] [Full Text] [Related]

  • 35. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
    Nguyen KS, Kobayashi S, Costa DB.
    Clin Lung Cancer; 2009 Jul 11; 10(4):281-9. PubMed ID: 19632948
    [Abstract] [Full Text] [Related]

  • 36. Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells.
    Tani T, Yasuda H, Hamamoto J, Kuroda A, Arai D, Ishioka K, Ohgino K, Miyawaki M, Kawada I, Naoki K, Hayashi Y, Betsuyaku T, Soejima K.
    Mol Cancer Ther; 2016 Jan 11; 15(1):162-71. PubMed ID: 26682573
    [Abstract] [Full Text] [Related]

  • 37. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S.
    Mol Cancer Ther; 2012 Oct 11; 11(10):2149-57. PubMed ID: 22844075
    [Abstract] [Full Text] [Related]

  • 38. Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
    Martinez-Marti A, Felip E, Matito J, Mereu E, Navarro A, Cedrés S, Pardo N, Martinez de Castro A, Remon J, Miquel JM, Guillaumet-Adkins A, Nadal E, Rodriguez-Esteban G, Arqués O, Fasani R, Nuciforo P, Heyn H, Villanueva A, Palmer HG, Vivancos A.
    Ann Oncol; 2017 Oct 01; 28(10):2451-2457. PubMed ID: 28961841
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.